Study Condition(s): Type 2 Diabetes
A Study of U-500 Insulin (Humulin LY041001) in Participants With Type 2 Diabetes
Study Alias: IBHG
The purpose of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have type 2 diabetes mellitus (T2DM)
Participant must be currently using U-100 insulin analog with a total daily dose of greater than 200 units and have a total daily dose of less than or equal to 3.0 units per kilogram; basal; premixed; or basal/bolus by any injection device
Participant must be on concomitant antihyperglycemic agent(s) which may include metformin (MET), dipeptidyl peptidase 4 inhibitors, pioglitazone, glucagon like peptide (GLP)-1 receptor agonists which must have been stable for ≥3 months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4 months)
Participant must not have type 1 diabetes mellitus (T1DM) or other types of diabetes mellitus
Participant must not have known hypersensitivities or allergies to insulin
Participant must not have used U-500R within 3 months prior to screening
Participant must not have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia